---
schema_version: "secwatch.filing_event.v1"
accession: "0001728117-25-000069"
form_type: "8-K"
ticker: "GOSS"
cik: "0001728117"
company_name: "Gossamer Bio, Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:51:20.133377+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Gossamer Bio Q2 net loss $38.3M; PROSERA Phase 3 topline due Feb 2026

## Summary
- Net loss $38.3M ($0.17 per share) vs net income $49.2M in Q2 2024, driven by $88.8M one-time license revenue in prior year.
- Cash, equivalents and marketable securities $212.9M as of June 30, 2025; runway into 2027.
- PROSERA Phase 3 PAH study enrolled 390 patients; topline results expected February 2026.
- SERANATA Phase 3 PH-ILD study first site activations planned Q4 2025; 480-patient, 24-week trial.
- Collaboration revenue $11.5M (mostly cost reimbursement from Chiesi) vs $95.8M in Q2 2024.

## SEC filing metadata
- accession: 0001728117-25-000069
- form_type: 8-K
- ticker: GOSS
- cik: 0001728117
- company_name: Gossamer Bio, Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728117/000172811725000069/0001728117-25-000069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728117/000172811725000069/goss-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001728117-25-000069
- JSON: https://secwatch.observer/filing/0001728117-25-000069.json
- Plain text: https://secwatch.observer/filing/0001728117-25-000069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.